Shandong Kexing Bioproducts Co. Ltd. A (688136) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of Shandong Kexing Bioproducts Co. Ltd. A stock ¥9.79, price ¥15.53, that is 37.0% below the price, quality 59 out of 100. Rating: strongly overvalued. Calculated from audited financials with 25 of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 7, 2026.
How to read this chart
60‑month range ¥11.43 – ¥60.83 · fair‑value band ¥5.37 – ¥15.69 · the ¥15.53 price screens above the ¥9.79 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). 1 fiscal year is left out: there the valuation rested on only a fraction of the usual models. As of Nov 7, 2026.
Follow Shandong Kexing Bioproducts Co. Ltd. A in your weekly email
Every Wednesday you see whether Shandong Kexing Bioproducts Co. Ltd. A is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Kexing Biopharm Co., Ltd., a biopharmaceutical company, engages in the research and development, production, and sale of recombinant protein drugs and microecological preparations in China, the European Union, Brazil, the Philippines, and Indonesia.
Show moreShow less
The company focuses on oncology, immunology, and degenerative diseases; and develops new antibodies, proteins, nucleic acid drugs, and antiviral therapy, as well as for the treatment of tumor, autoimmune, metabolic diseases, and other therapeutic fields.
It also develops GB05 human interferon a1b inhalation solution that is in Phase III clinical trial; GB-K02, an human granulocyte colony-stimulating factor injection in Phase III clinical trial; GB08, an growth hormone that has completed Phase I clinical trial; GB10 for fundus diseases; GB12 for atopic dermatitis; GB18 for cancer cachexia; GB23 for solid tumors; GB24 for inflammatory bowel diseases; and GB25, an tri-specific antibody for colorectal cancer.
In addition, the company's products include drugs, such as human erythropoietin, human interferon a1b and human granulocyte colony-stimulating factor injections, albumin-bound paclitaxel, infliximab injection, combined clostridium butyricum, and bifidobacterium powder/capsule.
Kexing Biopharm Co., Ltd. was founded in 1997 and is based in Jinan, China.
Stock analysis
Shandong Kexing Bioproducts Co. Ltd. A (688136) currently trades at ¥15.53, while our model-based Fair Value estimate is ¥9.79, 37% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of ¥15.47 per share, and 4 of the 25 models we run sit above the ¥15.53 price.
Bear case: the Growth DCF group reads lowest at ¥2.44, and 21 of the 25 models stay below the price. Data coverage for this calculation is high.
Scenario range: ¥5.37 (bear) to ¥15.69 (bull), the price of ¥15.53 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 59/100 (solid quality), in the Healthcare sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Shandong Kexing Bioproducts Co. Ltd. A reported revenue of 1.5B CNY in FY2025 versus 1.3B CNY in FY2021, a compound +4.6%/yr. Reported net income was 159M CNY in FY2025, compounding +13.4%/yr from FY2021.
Key figures
Market cap 3.0B CNY (≈ $452M) Small · P/E ratio 14.7 · P/S ratio 2.10 · EPS (TTM) ¥1.06 · Dividend yield 1.6% · Net margin 14.5% · Return on equity 11.7% · Return on assets (EBIT) −0.5% (5-year average).
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 42 out of 100 (low confidence).
What moves the price
The share trades about 59% below its 52-week high and 3% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at −37%, 688136 screens richer than that median.
Fair Value models
Bear¥5.37Fair Value ¥9.79Bull¥15.69
Price ¥15.53 · Downside -37.0%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then (¥0.6946 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.53/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+9.5%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+5.4%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+4.8%
Start year 2020 (pandemic)
Revenue growth 8 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+12.1%
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
−1.1%
Earnings growth per share plus dividend.
Earnings per share, growth per year−2.7%
Dividend (yield on the price)1.6%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.13% → 11%
⚠ Revenue per share shrinking 5.5%/yr over ~6Y (margins eroding too) ⓘStructural-decline marker: revenue PER SHARE has fallen over the last decade (robust median trend, not a single year). Backtested across 2005 to 2017, such businesses trailed the market by about 2.5 percentage points per year. Display only: it does not change the fair value or the quality score.
Compare Shandong Kexing Bioproducts Co. Ltd. A with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 558 stocks
Beats the industry median on 9/13 measures
Overall it ranks above its industry peers.
Valuation
Quality Score59 · Top 25%
Fair Value upside−37.0% · Above median
Profitability
Return on equity (12 months)11.7% · Top 25%
Return on assets4.5% · Top 25%
Net margin (12 months)14.5% · Above median
Operating margin (12 months)−20.4% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY)−5.9% · Below median
Dividend yield (12 months)1.6% · Above median
Balance sheet
Debt / equity0.42× · Highest 25%
Valuation Multiplesvs Biotechnology median · lower = cheaper
P/E (12 months)14.7× · Cheaper than median
P/B1.72× · Cheaper than median
P/S (12 months)2.10× · Cheapest 25%
EV/EBITDA55.9× · Priciest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 0
FUTURE (revenue growth)0· sector 0
PAST (return on equity)47· sector 0
HEALTH (low debt)79· sector 97
DIVIDEND (yield)32· sector 22
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Shandong Kexing Bioproducts Co. Ltd. A Fair Value". https://www.fairvalue-calculator.com/stock/688136
Frequently asked questions
Is Shandong Kexing Bioproducts Co. Ltd. A (688136) overvalued or undervalued?
As of Nov 7, 2026, our model estimates a fair value of ¥9.79 versus a price of ¥15.53, about 37% lower (overvalued).
What is the fair value of 688136?
Our model-based fair value for Shandong Kexing Bioproducts Co. Ltd. A is ¥9.79 (as of Nov 7, 2026), built from audited fundamentals. The current price: ¥15.53.
What is the quality score of 688136?
Shandong Kexing Bioproducts Co. Ltd. A has a Quality Score of 59/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Shandong Kexing Bioproducts Co. Ltd. A (688136)?
Our model-based price target is the fair value of ¥9.79 (as of Nov 7, 2026) from 25 valuation models. Cautious scenario ¥5.37, optimistic scenario ¥15.69. It is a calculation from audited fundamentals, not an analyst target.
What is the Shandong Kexing Bioproducts Co. Ltd. A stock forecast for 2026?
Our models put fair value at ¥9.79, about 37% lower versus a price of ¥15.53 (overvalued). Cautious scenario ¥5.37, optimistic scenario ¥15.69. The calculation is refreshed regularly with new filings.
What is the revenue of Shandong Kexing Bioproducts Co. Ltd. A (688136)?
Shandong Kexing Bioproducts Co. Ltd. A reported trailing-twelve-month revenue of about 1.4B CNY (latest available figure, as of Nov 7, 2026).
Does Shandong Kexing Bioproducts Co. Ltd. A pay a dividend?
Shandong Kexing Bioproducts Co. Ltd. A currently shows a dividend yield of 1.61% relative to its recent price (as of Nov 7, 2026).
How much is the dividend of Shandong Kexing Bioproducts Co. Ltd. A (688136) and when is the ex-dividend date?
Shandong Kexing Bioproducts Co. Ltd. A pays a dividend of ¥0.25 per share a year, a dividend yield of 1.6%. The last ex-dividend date was Jun 15, 2026. The payout ratio is 24.9% of earnings (on adjusted earnings, reported 23.6%). Free cash flow covers the dividend 0.05 times. Our assessment: Watch coverage. The dividend isn’t fully covered by free cash flow or earnings, part of it is funded from reserves or debt. Fine for now, but worth watching: if it stays uncovered, the dividend could be cut.
What is the intrinsic value of Shandong Kexing Bioproducts Co. Ltd. A (688136)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Shandong Kexing Bioproducts Co. Ltd. A it is ¥9.79 per share (as of Nov 7, 2026), against a price of ¥15.53. It is the blended result of 25 valuation models in 8 families (DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings).
Is Shandong Kexing Bioproducts Co. Ltd. A stock overvalued or undervalued in 2026?
As of Nov 7, 2026, 688136 trades above its calculated fair value: price ¥15.53, fair value ¥9.79, a gap of about −37% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 688136?
No. The price is what the market pays today (¥15.53); the fair value is what the company's own numbers justify (¥9.79). For Shandong Kexing Bioproducts Co. Ltd. A the two are ¥5.74 per share apart. That gap is exactly why we show both numbers side by side.
How much is Shandong Kexing Bioproducts Co. Ltd. A worth?
The market values Shandong Kexing Bioproducts Co. Ltd. A at about 3.0B CNY (market capitalisation, as of Nov 7, 2026). Per share that is ¥15.53; our models calculate a fair value of ¥9.79 per share.
What do the bullish and bearish scenarios say about 688136?
Our models span a range for Shandong Kexing Bioproducts Co. Ltd. A: cautious scenario ¥5.37, base ¥9.79, optimistic ¥15.69 per share (as of Nov 7, 2026, price ¥15.53). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 688136?
Shandong Kexing Bioproducts Co. Ltd. A trades at a price-to-earnings ratio of 14.7 (as of Nov 7, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of ¥9.79 is built from several models across several years. Excluding one-off items of fiscal year 2025 it is 19.7 (reported for FY2025: 18.6). Other multiples: P/B 1.7, P/S 2.1, EV/EBITDA 55.9.
How solid is the balance sheet of Shandong Kexing Bioproducts Co. Ltd. A (688136)?
Balance-sheet figures for Shandong Kexing Bioproducts Co. Ltd. A (as of Nov 7, 2026): return on equity 11.7%, debt of 0.42 per unit of equity. They feed the Quality Score of 59/100, which measures business quality independently of the share price.
How far is 688136 from its 52-week high?
Shandong Kexing Bioproducts Co. Ltd. A trades at ¥15.53, about 59% below its 52-week high of ¥37.55 and 3% above the low of ¥15.12 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of ¥9.79 is for.
Which stocks are comparable to Shandong Kexing Bioproducts Co. Ltd. A?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, CSL Limited, argenx SE, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Shandong Kexing Bioproducts Co. Ltd. A stock attractive at the current price?
The data as of Nov 7, 2026: price ¥15.53, calculated fair value ¥9.79 (−37%), Quality Score 59/100, from 25 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 688136 calculated?
We run Shandong Kexing Bioproducts Co. Ltd. A through 25 models from 8 families: DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of ¥9.79 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Shandong Kexing Bioproducts Co. Ltd. A itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Shandong Kexing Bioproducts Co. Ltd. A (688136)?
The closing price on Nov 6, 2026 was ¥15.53. Our model-based fair value is ¥9.79, about 37% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Shandong Kexing Bioproducts Co. Ltd. A right now?
The model range is unusually wide (¥5.37 to ¥15.69). The outcome hinges heavily on assumptions, so read the point estimate with caution. Solid but not exceptional quality (59/100) and above fair value, neither a clear bargain nor a standout compounder.
Key figures of Shandong Kexing Bioproducts Co. Ltd. A
How large is the market capitalisation of Shandong Kexing Bioproducts Co. Ltd. A (688136)?
The market capitalisation of Shandong Kexing Bioproducts Co. Ltd. A is 3.0B CNY (≈ $452M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Shandong Kexing Bioproducts Co. Ltd. A (688136)?
The price-to-sales ratio of Shandong Kexing Bioproducts Co. Ltd. A is 2.10 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Shandong Kexing Bioproducts Co. Ltd. A (688136)?
Earnings per share at Shandong Kexing Bioproducts Co. Ltd. A are ¥1.06 (price ÷ EPS = P/E 14.7). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Shandong Kexing Bioproducts Co. Ltd. A (688136)?
The dividend yield of Shandong Kexing Bioproducts Co. Ltd. A is 1.6% (payout 24.9%, on adjusted earnings, reported 23.6%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Shandong Kexing Bioproducts Co. Ltd. A (688136)?
The net margin of Shandong Kexing Bioproducts Co. Ltd. A is 14.5% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Shandong Kexing Bioproducts Co. Ltd. A (688136)?
The return on equity (ROE) of Shandong Kexing Bioproducts Co. Ltd. A is 11.7% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Shandong Kexing Bioproducts Co. Ltd. A (688136)?
On an EBIT basis the return on assets of Shandong Kexing Bioproducts Co. Ltd. A is −0.5% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Shandong Kexing Bioproducts Co. Ltd. A (688136)?
The operating margin of Shandong Kexing Bioproducts Co. Ltd. A is −20.4% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Shandong Kexing Bioproducts Co. Ltd. A (688136)?
Revenue at Shandong Kexing Bioproducts Co. Ltd. A is growing −5.9% versus a year earlier (3y avg +5.4%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Shandong Kexing Bioproducts Co. Ltd. A (688136)?
Earnings per share at Shandong Kexing Bioproducts Co. Ltd. A are growing +192% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Shandong Kexing Bioproducts Co. Ltd. A (688136) generate?
The free cash flow of Shandong Kexing Bioproducts Co. Ltd. A is 2.4M CNY (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Shandong Kexing Bioproducts Co. Ltd. A (688136) carry?
The net debt of Shandong Kexing Bioproducts Co. Ltd. A is 240M CNY (fiscal year 2025, ≈ 100.0 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Shandong Kexing Bioproducts Co. Ltd. A in the live analysis
One click puts Shandong Kexing Bioproducts Co. Ltd. A on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Broad data
Nov 7, 2026